Highlights
1 patent
About
Targeted Therapy to Prevent Resistance to Cancer Drugs
TyrNovo is developing a cancer treatment that eliminates a key protein, an approach that has the potential to improve cancer therapy, prevent drug resistance, and increase life expectancy. The companys novel approach promotes the degradation of insulin-receptor substrates 1 and 2. While targeted anticancer drugs inhibit the on signal, TyrNovos compounds activate the off switch, extensively blocking major oncogenic pathways. The compounds NT157 and NT219 have been licensed exclusively by TyrNovo from Yissum Research Development Company of the Hebrew University of Jerusalem. TyrNovos activity has been entirely integrated into Kitov Pharmaceuticals.
Identity
| Name | TyrNovo |
|---|---|
| Slug | tyrnovo |
| Type / kind | startup |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgJ3QjIwKDA |
Status
| Status | inactive |
|---|---|
| Status reason | Acquired (Inactive) by Purple Biotech on Jan 2017 - closed due to acquisition |
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | Center District |
| HQ city | Herzliya |
| HQ address | Herzliya, Israel |
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsCells
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business models
B2B
Tags
cancerpersonalizationbiopharmaceuticaldrug-discoveryoncologypharma-companies
Funding
| Total raised | — |
|---|---|
| Current stage | Acquired |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}